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238 Relation between fatty acid (FA) composition and clinical
status/genotype in CF?
S. Van Biervliet1, G. Van Billemont2, D. Declercq1, M. Genetello1,
A. Christophe2, E. Robberecht1. 1Paediatric Gastroenterology, Ghent university,
Ghent, Belgium; 2Endocrinology, Ghent university, Ghent, Belgium
Aim: evaluate the relation of clinical parameters & genotype with the serum
phospholipids FA composition in CF patients.
Methods: CF patients, with stable pulmonary disease, followed for min 6 m were
taken a blood sample for phospholipids FA composition & vitamin E concentration.
The genotype, age, pancreatic function, nutritional status, caloric intake, pulmonary
function & presence of pseudomonas colonisation, liver disease or diabetes mellitus
were recorded. Patients were divided in 2 groups according to genotype (group A:
mutation class I, II, or III, group B: mutation class IV, V).
Results: CF patients (group A and B together) have signiﬁcant lower docosa-
hexaenoic acid (DHA) (P< 0.007) and linoleic acid (LA) (P< 0.0001) and higher
dihomogammalinolenic acid (DHGLA) (P< 0.0001), oleic acid (OA) (P< 0.0001)
and mead acid (MA) (P< 0.0001), resulting in an increased ratio of arachidonic
acid (AA)/DHA (P< 0.004), MA/AA (p< 0.0001) and OA/LA (P< 0.0001).
Group A had compared to group B a lower LA (p< 0.002) and a higher DHGLA
(p< 0.002), 22:4 w6 (p< 0.03), 22:5 w6 (p< 0.03) and 20:3 w9 (p< 0.04). There
was however no signiﬁcant difference between the groups for pulmonary function,
nutritional status, age, vitamin E concentration. There was no relation of FA
with gender, pulmonary function, pseudomonas colonisation, diabetes mellitus,
pancreatic function, nutritional status or caloric intake. Patients with CF liver disease
had an even lower DHA than the patients of the same genotype.
Conclusion: Fatty acid disturbances are related to genotype and the presence of
CF related liver disease. Future studies should take these parameters into account.
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Background: Essential fatty acids deﬁciency (EFAD) has been reported for more
than 40 years. Its most frequent symptoms are: skin lesions, increased susceptibility
to infections, impaired growth and hepatic steatosis. Although etiology of EFAD
is still unknown, it is clear that correction of this defect via: nutrition, oral
supplementation or intravenous administration can improve health status of CF
patients.
Aim: Assessment of serum levels of linoleic acid (LA), a-linolenic acid (aLnA)
and arachidonic acid (AA) in Slovak CF patients and correlation of the estimated
levels with pancreatic insufﬁciency (PI), BMI and FEV1.
Methods: 79 patients with CF and 40 healthy persons as controls were included into
the study. Fatty acids concentrations were estimated in serum samples by capillary
gas chromatography and quantiﬁed in mg/ml.
Results: Patients with CF had signiﬁcantly lower concentrations of LA (16.4±2.9)
than healthy controls (21.8±4.7). Comparison of LA levels between the PI subgroup
(16.5±3.0) and the non-PI patients (15.7±1.8) showed that decreased concentration
of LA is not related to pancreatic functions. Levels of aLnA in the serum samples of
the CF patients were small (1.0±1.1) but not signiﬁcantly different from the controls
(1.8±0.4). Concentration of AA in the CF patients (3.7±1.4) was slightly higher
in comparison with the controls (2.1±0.6) what is in consonance with previously
published data.
Conclusions: The study can support the hypothesis that EFAD is a result of an
increased demand for linoleic acid due to increased production of its metabolite –
arachidonic acid.
240 Inﬂuence of pancreatic status on plasma and erythrocyte
membrane fatty acid composition in CF
T.C. Coste, G. Deumer, G. Reychler, F. Wustefeld, P. Lebecque, T. Leal,
P. Wallemacq. Universite´ Catholique de Louvain, Brussels, Belgium
Abnormal fatty acid (FA) composition in plasma (P) and erythrocyte membrane
(RBC) has been increasingly reported in CF. Discrepancies have been described
and could be related, at least partly, to the pancreatic status (Coste 2007). P and
RBC FA compositions were analysed by GC-MS method using a 30m× 0.25mm
ID column after transesteriﬁcation with acetyl chloride in 68 CF patients (median
age = 14.5 y) and 29 age-matched controls. CF patients were categorized according
to the pancreatic status as sufﬁcient (PS) or insufﬁcient (PI).
PI patients displayed signiﬁcantly lower linoleic acid (LA) and docosahexaenoic
acid (DHA). A decreasing trend (p = 0.08) was noted for DHA in PS patients.
The product LAxDHA appeared reduced in both CF groups and reached statistical
signiﬁcance (p< 0.0001) in PI patients as compared to controls. These results
indicate that pancreatic status plays a major role in circulating and cellular fatty
acid composition in CF.
Plasma and erythrocyte LA and DHA levels in CF patients according to the pancreatic
status
FA (g/100 g) Controls (n = 29) CF PS (n = 12) CF PI (n = 56)
LA P 25.6±5.2 27.0±2.7 20.3±5.1a+b
LA RBC 8.3±1.0 8.5±0.7 7.1±1.3a+b
DHA P 1.9±0.7 1.6±0.5 1.4±0.6a
DHA RBC 4.5±1.0 4.0±1.1 3.5±1.1a
Data are expressed as means ± SD. Statistical differences at p-value level <0.0003 are
indicated for comparison between PI and acontrol or bPS group.
Supported by: FSR (UCL) and French (VLM) and Belgian (ABLM) CF associa-
tions.
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Glucose tolerance varies in people with Cystic Fibrosis (CF) over time. Hypergly-
caemia may develop in individuals without CF Related Diabetes (CFRD) on steroids
or during exacerbations. The UKCF Trust recommend measuring blood glucose on
admission, pre and post meals, pre, 2 hours into and post enteral tube feeding, and
considering insulin if levels are persistently raised (>7mmols/L) at any time.
Aim: To compare blood glucose monitoring with UKCF Trust Guidelines.
Methods: From November-December 2006, all CF patients admitted with an
exacerbation underwent blood glucose monitoring (n = 10) aged 18−33 years, mean
BMI 19.7 (15.7−21.5). Based on the most recent oral glucose tolerance test, 30%
had normal glucose tolerance (NGT), 30% had impaired glucose tolerance (IGT)
and 40% had CFRD (75% on insulin). Monitoring was compared with UKCF Trust
Guidelines.
Results: 20% of patients had blood glucose measured on admission. In the
NGT group, the mean frequency of pre and post meal monitoring was 4% compared
with 32% and 5% in the IGT group, and 57% and 26% in the CFRD group. The
mean BMI of the IGT group was 17.9 and all were on enteral feeding. The mean
frequency of pre, 2 hours into and post feed monitoring in this group was 60%, 70%
and 30% respectively. Of which, a mean 34% of pre feed, 96% of 2 hours into and
53% of post feed values were >7mmols/L. However, insulin was not commenced.
Within the CFRD group, mean pre and post meal values >7mmols/L were 85%
and 83% respectively.
Conclusion: In our group of undernourished patients, blood glucose monitoring was
inconsistent and sub-optimal compared with UKCF Trust Guidelines. Management
of glycaemic status during an exacerbation was therefore difﬁcult to assess. Results
suggest that some patients should have been considered for insulin treatment.
